BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230411
DTEND;VALUE=DATE:20230414
DTSTAMP:20260516T054600
CREATED:20230216T110911Z
LAST-MODIFIED:20230216T110911Z
UID:36612-1681171200-1681430399@www.pharmajournalist.com
SUMMARY:3rd Annual Ligase Targeting Drug Development Summit
DESCRIPTION:Hijacking E3 Ligases to Mediate Degradation & Modulation of Undrugged Targets \nAs a family of over 600 known proteins\, ligases pose immense potential as viable avenues for harnessing previously undrugged targets. Key challenges remain however to rapidly discover and identify novel and underexploited ubiquitin E3s. Furthermore\, bottlenecks exist in the development of the established ligases; Cereblon and VHL. \n \nIt is now critical that we harness Cryo-EM\, X-Ray crystallography\, and other visualization tools to fully understand the structure and function of these lesser-known E3s\, accelerate ligand screening with new and improved tools\, leverage advances in DMPK knowledge to address concerns over toxicity in Cereblon\, propel VHL from ‘academic’ to clinic\, and all in\, de-risk the translation of candidate ligases to the clinic. \nThe 3rd Ligase Targeting Drug Development Summit is returning with fresh understanding and data from the forerunners of the field and those who have recently joined the space. Together we will investigate ligase structural and functional biology\, screening tools for optimal ligase\, linker\, and ligand identification\, explore tissue specificity\, uncover the key modalities where ligases can succeed\, and showcase the novel assays that are maximizing validation to ensure success in the clinic. \nThis dedicated forum will provide an unrivaled meeting point for industry leaders all under one specialized forum to strategically accelerate and de-risk the process of identifying\, validating\, and therapeutically leveraging cell and tissue-specific ubiquitin E3 ligases for degradation or modulation of targets in oncology\, immunology\, and beyond. \nTo know more: https://ter.li/gapgsb
URL:https://www.pharmajournalist.com/event/3rd-annual-ligase-targeting-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR